Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAmbetter Nevada definitive drug testing Policy Upd…
    Ask Trek AI about this page
    CurrentAmbetter NevadaPolicy CP.MP.50

    Drugs of Abuse: Definitive Testing

    Customize your policy alerts

    Sign up for Ambetter Nevada Policy CP.MP.50 alerts

    Get alerted when Policy CP.MP.50 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Coverage policy defining medical necessity, coding, and prior authorization protocols for definitive drugs-of-abuse testing (e.g., GC/MS, LC/MS) for Ambetter Nevada members/enrollees. Affects ordering providers, laboratories, and billing for definitive drug testing.

    Policy Summary
    PayerAmbetter Nevada
    PolicyDrugs of Abuse: Definitive Testing
    Policy CodePolicy CP.MP.50
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization when required; tests for children under 6 are exempt and PA may be accepted up to 10 business days after collection.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    G0482,G0483HCPCS codes not supporting coverage
    Multiple CPTCoding table updates
    <6PA exempt: age
    10 daysPA post-collection window

    Coverage Criteria

    Medically necessary indications (summary)

    Covered when policy‑specified medical necessity criteria are met.

    General covered scenarios: Blanket orders; reflex definitive testing when presumptive testing is performed at point of care; physician standing orders for all patients; billing codes for individual drugs which are included in a billed panel; presumptive immunoassay testing in a laboratory when presumptive point‑of‑care testing has been performed; presumptive screening before definitive testing if presumptive testing was not ordered; immunoassay (IA) testing used to confirm a presumptive test result obtained by cups, dipsticks, cards, cassettes or other CLIA‑waived methods.

    Detailed numbered criteria (I/II/III) referenced in policy; see full policy for itemized conditions.

    Presumptive drug testing criteria have been removed from this policy and are now addressed under CP.MP.208 (Drugs of Abuse: Presumptive Testing). This policy focuses on definitive testing and the medical necessity criteria that support coverage, including blanket orders, reflex definitive testing following point-of-care presumptive testing, physician standing orders, billing for individual drugs included in a panel, and laboratory-based presumptive immunoassay testing when point-of-care testing was performed. The policy revisions added and removed CPT entries over time and explicitly designated a set of CPT codes as not medically necessary; users should follow the coding tables in this policy and refer to CP.MP.208 for presumptive testing rules.

    The policy identifies HCPCS codes G0482 and G0483 as codes that do not support the coverage criteria. In addition, specific CPT codes listed in the policy (including codes added as not medically necessary such as 0143U–0150U and later additions like 0328U) are designated as not supporting coverage decisions. Billing with these HCPCS or CPT codes may not meet medical necessity per the policy coding tables and should be avoided when seeking coverage for definitive testing.

    Indications Covered

    Definitive testing following an appropriate presumptive test or where definitive testing is clinically indicated

    Definitive testing is covered when one or more of the following clinical circumstances are met:

    Definitive testing following appropriate presumptive testing: Reflex definitive testing after an appropriate presumptive test (including point‑of‑care presumptive testing) when confirmation or quantitation is clinically indicated.

    Reflex testing covered when presumptive POC testing performed; physician standing orders may trigger reflex testing.

    Standing or blanket orders: Physician standing orders or blanket orders that specify definitive testing for patients where clinical management requires definitive identification or quantitation of drugs.

    Policy recognizes blanket and standing physician orders as valid indications for definitive testing.

    When quantitative levels are required for clinical management: Definitive methods (e.g., GC/MS, LC/MS) when quantitative drug levels are required to guide treatment decisions or monitoring.

    Coding

    Covered HCPCS (methods supporting coverage criteria)HCPCSCovered
    unspecified HCPCS (definitive methods description)HCPCS codes that support coverage criteria: definitive methods (GC/MS, LC/MS), excluding immunoassays; qualitative or quantitative; includes specimen validity testing, per day, any number of drug classes
    HCPCS codes that do not support coverage criteriaHCPCSNot Covered
    G0482Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers; includes specimen validity testing, per day; 15 to 21 drug class(es), including metabolite(s) if performed.
    G0483Drug test(s), definitive, utilizing drug identification methods able to identify individual drugs and distinguish between structural isomers; includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed.
    CPT codes referenced in policy (added/removed over time)CPT
    0143UCPT code listed as not medically necessary (deleted later)
    0144UCPT code listed as not medically necessary (deleted later)
    0145UCPT code listed as not medically necessary (deleted later)
    0146UCPT code listed as not medically necessary (deleted later)
    0147UCPT code listed as not medically necessary (deleted later)
    0148UCPT code listed as not medically necessary (deleted later)
    0149UCPT code listed as not medically necessary (deleted later)
    0150UCPT code listed as not medically necessary (deleted later)
    80367Added to coding tables supporting coverage criteria
    80368Added to coding tables supporting coverage criteria
    1–10 of 17
    1/2

    Provider Actions & Billing

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for definitive drugs-of-abuse testing except where noted below. Testing for children under 6 years of age is exempt from prior authorization. Prior authorization requests will be accepted up to 10 business days after specimen collection and will be reviewed for medical necessity based on the policy criteria.

    • PA not required for patients < 6 years of age
    • PA requests accepted up to 10 business days after specimen collection
    Denial Risk

    Coding Mismatches May Trigger Denial

    Coding that does not match the policy-supported CPT/HCPCS codes (including codes listed as not supporting coverage) may lead to claim denial or non-coverage decisions. Verify that billed CPT/HCPCS codes align with the policy's covered code lists and medical necessity criteria before submission.

    Ordering Requirements

    Note

    Ordering: reflex definitive testing allowed after presumptive POC test

    Reflex definitive testing is covered when performed after an appropriate presumptive test at the point of care; physician standing orders and blanket orders are recognized as valid ordering mechanisms.

    • Definitive testing supported following appropriate presumptive POC testing
    • Physician standing orders and blanket orders are acceptable for ordering reflex testing

    Not Covered

    Definitive testing billed using HCPCS G0482 or G0483, or with CPT codes the policy designates as not supporting coverage criteria, is identified as not covered. Claims submitted with these specific HCPCS/CPT codes do not meet the policy’s coding requirements for definitive drugs-of-abuse testing and may be denied for lack of medical necessity. Providers and laboratories must code tests in accordance with the policy’s coding tables to support coverage.

    Definitions

    inv-12: Definitive testing — lab methods
    Definition (term)Definitive testing: laboratory methods able to identify individual drugs and distinguish structural isomers (e.g., GC/MS, LC/MS, single or tandem) with method- or drug-specific calibration, matrix-matched quality control, and use of stable isotope or other universally recognized internal standards per specimen.
    Included methodsGC/MS and LC/MS (single or tandem) qualitative or quantitative testing; includes specimen validity testing, per day, any number of drug classes.
    ExclusionsImmunoassays and enzymatic methods (e.g., IA, EIA, ELISA, EMIT, FPIA, alcohol dehydrogenase) performed without method- or drug-specific calibration, matrix-matched QC, or appropriate internal standards are not considered definitive methods.
    Laboratory quality expectationsUse of method- or drug-specific calibration, matrix-matched quality control material, and stable isotope or other universally recognized internal standard(s) for each drug, metabolite, or drug class per specimen.
    inv-13: Presumptive testing — immunoassay-based methods

    Frequency Limits

    inv-15: presumptive/definitive testing interplay
    Policy changePresumptive drug testing limits for chronic opioid therapy were added to section I.B of the policy (presumptive/definitive testing interplay).
    Interplay summaryPolicy recognizes reflex definitive testing after appropriate presumptive POC testing, and that presumptive screening may precede definitive testing when presumptive testing was not originally ordered.
    Clinical implicationPresumptive testing performed at point of care can trigger reflex definitive testing; limits on presumptive testing frequency in chronic opioid therapy were explicitly added to criteria.

    Background

    Definitive drug testing in this policy is defined to use analytical methods capable of identifying individual drugs and distinguishing structural isomers — for example, GC/MS or LC/MS (single or tandem) — with method- or drug-specific calibration, matrix-matched quality control, and the use of stable isotope or other universally recognized internal standards. The HCPCS descriptions for definitive testing (e.g., G0482/G0483) explicitly reference these requirements, and the policy treats immunoassay methods (IA, EIA, ELISA, EMIT, FPIA) as presumptive screening methods addressed in CP.MP.208.

    Policy Summary
    PayerAmbetter Nevada
    PolicyDrugs of Abuse: Definitive Testing
    Policy CodePolicy CP.MP.50
    Change TypeNo material changes
    Effective Date
    Next Review Date
    Key ActionSubmit prior authorization when required; tests for children under 6 are exempt and PA may be accepted up to 10 business days after collection.
    SourceLink
    On This Page
    Coverage CriteriaIndications CoveredCodingProvider Actions & BillingOrdering RequirementsNot CoveredDefinitionsFrequency LimitsBackground

    Definitive testing methods must meet laboratory standards described in the policy (see definitions and background).

    Reflex from point‑of‑care (POC) testing: Definitive testing performed as reflex when a presumptive POC immunoassay is positive or otherwise indicates need for confirmation.

    Includes IA testing used to confirm results obtained by CLIA‑waived POC methods.

    • Use only CPT/HCPCS codes that support coverage per the policy
    • Codes listed as not supporting coverage (e.g., specific U-codes added/removed in revisions) may trigger denial
    Prior Authorization

    Prior Authorization Timing and Exemptions

    Providers must submit prior authorization requests within the stated timing window unless the member is < 6 years of age (exempt). Requests received within 10 business days after specimen collection will be accepted and reviewed for medical necessity. Ensure documentation supports the medical necessity criteria at time of review.

    • PA acceptance window: up to 10 business days after specimen collection
    • Exemption: children < 6 years of age
    Documentation Required

    Provider Submission Guidance

    Follow payer instructions for submitting PA and clinical documentation. Incomplete or miscoded submissions increase the risk of denial or delay.

    • Include clinical rationale that meets the policy's medical necessity criteria
    • Confirm CPT/HCPCS codes align with policy-covered lists prior to submission
    Definition (term)Presumptive testing: immunoassay-based methods (e.g., IA, EIA, ELISA, EMIT, FPIA) used for initial screening.
    Policy locationPresumptive testing criteria were removed from this definitive-testing policy and are addressed in a separate policy: CP.MP.208 Drugs of Abuse: Presumptive Testing.
    Typical useUsed for initial/point-of-care screening (cups, dipsticks, cards, cassettes or other CLIA‑waived methods) and may be followed by definitive testing when indicated.
    Removed codesPresumptive testing CPT codes (e.g., 80305, 80306, 80307) were removed from this policy when presumptive criteria were relocated to CP.MP.208.